Specify a stock or a cryptocurrency in the search bar to get a summary
Akari Therapeutics PLC
AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210
Analytics
WallStreet Target Price
80 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AKTX
Dividend Analytics AKTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AKTX
Stock Valuation AKTX
Financials AKTX
Results | 2019 | Dynamics |